Avastin for Refractory Glioblastoma and Oxaliplatin for Colon Cancer

Article

As presented at ASCO, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28% response rate and an overall survival edge for refractory glioblastoma. Also presented at the ASCO meeting, adding oxaliplatin (Eloxatin) to a standard chemotherapy regimen for stage II or III colon cancer may provide a small five-year survival advantage.

Recent Videos
Wendy Wright, DNP, an expert on fibromyalgia
Developing Risk Assessment Tools for Viruses in School
Julie Harper, MD: Discussing Acne Treatment Updates, Unmet Needs Among Patients
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
What Do Patients Need to Learn About their Hypersensitivity Pneumonitis?
New Approaches to Treating Rosacea, with Hilary Baldwin, MD
Discussing Unmet Needs Among Patients in Dermatology, with Matthew Zirwas, MD
Review of Recent Advancements in Dermatology, with Matthew Zirwas, MD
Allison Moser, MSN, RN, FNP-BC | Credit: Allison Moser on LinkedIn
Related Content
Adding Brief CBT to Inpatient’s Usual Treatment Reduces Suicide Reattempts

Adding Brief CBT to Inpatient’s Usual Treatment Reduces Suicide Reattempts

Chelsie Derman
September 18th 2024
Article
Introducing The Medical Sisterhood, with Mona Shahriari, MD

Introducing The Medical Sisterhood, with Mona Shahriari, MD

Mona Shahriari, MD, FAAD
September 16th 2024
Podcast
Yuanteng Jeff Li, MD, RhMSUS, FACR, Assistant Professor, Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center,

IL-17/IL-23 Targeting Safely Managed PsA in 3 Patients With Cancer on Immune Checkpoint Inhibitor Therapy

Victoria Johnson
September 18th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: Real-World Experience with the Dexcom Stelo

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
September 12th 2024
Podcast
US FDA logo in black over a white background. | Credit: US Food and Drug Administration

FDA Approves Benralizumab for Eosinophilic Granulomatosis with Polyangiitis

Patrick Campbell
September 18th 2024
Article
US FDA logo in black over a white background. | Credit: US Food and Drug Administration

FDA Clears Eversense 365, Marking First 1-Year CGM Option in Diabetes

Patrick Campbell
September 18th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.